false
0000875045

0000875045

2026-06-09
2026-06-09

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities
Exchange Act of 1934

 

Date of Report (Date of earliest event reported):
June 9, 2026

 

 

Biogen Inc.

(Exact name of registrant as specified in its charter)

 

Delaware
0-19311
33-0112644

(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

 

225 Binney Street , Cambridge , Massachusetts 02142

(Address of principal executive offices; Zip Code)

 

Registrant’s telephone number, including area
code: (617) 679-2000

 

Not Applicable

(Former name or former address, if changed since
last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class
Trading Symbol(s)
Name of each exchange on which registered

Common Stock, $0.0005 par value per share
BIIB
The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

 

¨ Emerging
growth company

 

If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On June 9, 2026, Biogen Inc. (the “Company”) held its 2026
Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

 

1. Stockholders elected ten nominees to the Board of Directors to serve for a one-year term extending until the 2027 annual meeting of
stockholders and their successors are duly elected and qualified, with the votes cast as follows:

 

Nominee
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes

Maria C. Freire
 

103,033,121 

 
 

18,790,237 

 
 

84,064 

 
 

9,359,127 

 

William A. Hawkins
 

102,135,204 

 
 

19,683,098 

 
 

89,120 

 
 

9,359,127 

 

Susan K. Langer
 

103,931,406 

 
 

17,886,544 

 
 

89,472 

 
 

9,359,127 

 

Jesus B. Mantas
 

101,698,187 

 
 

20,117,077 

 
 

92,158 

 
 

9,359,127 

 

Lloyd Minor
 

121,220,738 

 
 

594,000 

 
 

92,684 

 
 

9,359,127 

 

Menelas Pangalos
 

121,130,060 

 
 

682,983 

 
 

94,379 

 
 

9,359,127 

 

Monish Patolawala
 

120,796,249 

 
 

1,016,057 

 
 

95,116 

 
 

9,359,127 

 

Eric K. Rowinsky
 

93,569,685 

 
 

28,216,589 

 
 

121,148 

 
 

9,359,127 

 

Stephen A. Sherwin
 

103,025,923 

 
 

18,788,272 

 
 

93,227 

 
 

9,359,127 

 

Christopher A. Viehbacher
 

121,127,966 

 
 

688,051 

 
 

91,405 

 
 

9,359,127 

 

 

2. Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2026, with the votes cast as follows:

  

 

Votes For
 
Votes Against
 
Abstentions
 

124,551,887
 
6,627,086
 
87,576
 

 

3. Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:

 

 

Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes

114,184,816
 
7,454,737
 
267,869
 

9,359,127 

 

 

 

 

 

 

 

Signatures

 

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

 

 

 
Biogen Inc.
 

 
 
 

 
 
 

 
By:
/s/ Wendell Taylor
 

 
 
Wendell Taylor
 

 
 
Secretary
 

Date: June 10, 2026